Psychiatric nurses considering long-term
|
|
- Edith Parks
- 6 years ago
- Views:
Transcription
1 XASIN_2_4_p146_150 10/25/04 4:11 PM Page 146 LONG-TERM EFFECTIVENESS OF ANTIPSYCHOTIC THERAPIES: CLINICAL CONSIDERATIONS Based on a presentation by Mary Ann Nihart, MA, APRN, BC* ABSTRACT This article summarizes findings from recent clinical investigations of the long-term effectiveness of antipsychotic therapies. Because schizophrenia is a lifelong illness, long-term clinical data, collected over a matter of weeks and not years, has limited application to clinical reality. However, it does provide some insights into drug efficacy over time, an important consideration in the prevention of relapse. Combined data from several studies demonstrate that the atypical agents are highly effective in preventing or increasing a patient s time to relapse, and significantly more effective as compared with the conventional agent haloperidol. Results from long-term studies of the newest antipsychotic, aripiprazole, are summarized with an emphasis on data surrounding cognitive function. Problems with cognition and verbal expression profoundly affect the nursing treatment plan and must be addressed in order to enhance recovery and to prevent relapse. Recommendations for assessing cognitive function and nursing interventions to help patients overcome such limitations are also provided. (Adv Stud Nurs. 2004;2(4): ) *Conference Coordinator Consultant and Partner, Professional Growth Facilitators, San Clemente, California; Faculty, University of California, Davis. Psychiatric nurses considering long-term therapeutic benefits are likely to think in terms of the patient s lifetime. Within a research context, however, long term is defined somewhat differently, since clinical trials must have an endpoint. Clinicians, then, are required to take somewhat of a leap of faith in applying long-term data to their daily practice, a circumstance that repeats itself in many of the clinical decisions made each day. Despite these limitations, the medical evidence provides a useful resource for clinicians in terms of descriptions of drug therapies that effectively prevent relapse in psychosis. Data show that although results surrounding long-term efficacy vary between agents, the atypical drugs as a class effectively increase time to relapse not only when compared with placebo but also when compared with conventional therapies. A 52-week study comparing olanzapine with haloperidol in patients with schizophrenia, schizophreniform, or schizoaffective disorders who responded to acute-phase therapy reported that, after 1 year of therapy, risk of rehospitalization in patients taking olanzapine was 19.7% versus 28% in those patients taking haloperidol. 1 An 800-day study of risperidone versus haloperidol in patients with stable chronic schizophrenia or schizoaffective disorder showed a 34% risk of relapse with risperidone versus 60% risk of relapse with haloperidol, as measured by a 25% increase in Positive and Negative Syndrome Scale (PANSS) total and a Clinical Global Impression of Improvement score of 6 or greater. 2 Finally, a study comparing ziprasidone with placebo showed that risk of relapse was similar with 80-mg daily (35%) and 146 Vol. 2, No. 4 October 2004
2 XASIN_2_4_p146_150 10/25/04 4:11 PM Page mg daily doses of ziprasidone (36%) versus placebo (77%). 3 This dose-adjusted study suggests that ziprasidone efficacy is not dose related; clinicians inclination to increase medication dose to achieve greater efficacy in stabilized patients is not supported by the medical evidence surrounding ziprasidone dosing. Combined, these studies demonstrate that the atypical agents are highly effective in preventing or increasing patient s time to relapse, and significantly more effective as compared with the conventional agent haloperidol. The atypical agents are not interchangeable, however; each has a unique pharmacologic and side-effect profile. A more detailed description of these characteristics is provided in the article by Dr McEnany (see page 135). The newest addition to the atypical drug class is aripiprazole, which has been evaluated in long-term clinical trials extending to 26 weeks and 52 weeks. In a 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study, Pigott et al compared 15-mg, fixed dose, once-daily dose of aripiprazole with placebo in 310 patients with chronic stable schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV. Of the 155 patients in each treatment group, 50 patients (34%) taking aripiprazole experienced relapse (relative risk, 0.59; P <.001) as compared with 85 patients (57%) taking placebo. 4 In a 52-week, randomized, double-blind, multicenter study, Kasper et al investigated the efficacy and safety of aripiprazole versus haloperidol in 1294 patients. 5 Aripiprazole demonstrated comparable efficacy to haloperidol across all symptoms measures, including significantly greater improvements in PANSS negative subscale scores and Montgomery Asberg Depression Rating Scale total score (P <.05). The time to discontinuation due to any reason and due to adverse events or lack of efficacy were significantly greater with aripiprazole as compared with haloperidol (P =.0001 for both). These findings suggest that fewer adverse effects are associated with aripiprazole, resulting in increased adherence to the medication regimen. At the same time, efficacy is shown to be sustained long term over the course of 52 weeks, with significant improvements in both positive and negative symptoms. Perhaps more importantly, a statistically significant and marked separation occurred between the haloperidol and aripiprazole study arms with regard to control of negative symptoms (Figure 1). 5 As shown in clinical practice, the conventional antipsychotics have not worked adequately to relieve negative symptoms of psychosis, and negative symptoms are more difficult and take longer to treat. The atypical agents represent an opportunity to treat negative symptoms effectively, allowing for improved psychosocial functioning in patients. EFFICACY VERSUS EFFECTIVENESS Studies of long-term efficacy influence daily decisions in clinical practices. But the gap existing between the outcomes demonstrated in clinical trials and those experienced in the real world of clinical care must be acknowledged. In the research setting assessments are precise, and patient samples are selected using rigorous inclusion/exclusion criteria. But the clinical world does not mirror the research setting. Dosing is highly variable, and concomitant medication use is likely. Clinicians are faced with the paradigm of clinical trial Figure 1. Aripiprazole 52-Week Study: Mean Change from Baseline in PANSS Negative Score *P <.05 between treatment groups; last observation carried forward. Baseline scores: aripiprazole, 24.7 (n = 853); haloperidol, 24.7 (n = 430). PANSS = Positive and Negative Syndrome Scale; LOCF = last observation carried forward. Adapted with permission from Kasper et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. 5 Advanced Studies in Nursing 147
3 XASIN_2_4_p146_150 10/25/04 4:11 PM Page 148 Symptoms of Cognitive Dysfunction MEMORY Difficulty retrieving and using stored memory Impaired short-term/long-term memory ATTENTION Difficulty maintaining attention Poor concentration Distractibility Inability to use selective attention FORM AND ORGANIZATION OF SPEECH (FORMAL THOUGHT DISORDER) Loose associations Tangentiality Incoherence/word salad/neologism Illogicality Circumstantiality Pressured/distractible speech Poverty of speech DECISION MAKING Failure to abstract Indecisiveness Lack of insight Impaired concept formation Impaired judgment Illogical or concrete thinking Lack of planning and problem-solving skills Difficulty initiating tasks THOUGHT CONTENT Delusions Paranoid Grandiose Religious Somatic Nihilistic Thought broadcasting Thought insertion Thought control Source: Moller MD, Murphy MF. Neurobiological responses and schizophrenia and psychotic disorders. In: Stuart GW, Laraia MT, eds. Principles and Practice of Psychiatric Nursing. 7th ed. St. Louis: Mosby; 2001: Copyright 2001 Elsevier. efficacy data as compared with the real-world experience of drug effectiveness. Research on real-world effectiveness is key to understanding the appropriate approach to antipsychotic therapy, and more research is needed in this area. COGNITION AND FUNCTIONAL OUTCOMES Cognition involves perception, awareness, and judgment needed for the brain to process information effectively. This cognitive process is impaired in people with schizophrenia due to problems with the brain s neurotransmitters, which prevent organization of sensory input into appropriate behavioral responses. Problems with attention, memory, learning, interpretation, and organization of sensory input result in impaired behavioral responses. 6 Psychiatric nurses must frequently assess symptoms of cognitive dysfunction, such as impaired memory, distractibility, speech problems, and delusions (see Sidebar) and may rely on the Mini-Mental Status Examination (MMSE) tool. However, the Neurobehavioral Cognitive Status Examination (NCSE; see Appendix) assesses a broader range of cognitive function than the MMSE, is brief enough to be administered in clinical settings, and has been shown to be more sensitive (86%) than the MMSE (3%) when traditional cutoff criteria for impairment were used (raw score <23 on the MMSE and 1 or more impaired scales on the NCSE). 7-9 The NCSE uses independent tests to evaluate function in 5 major cognitive ability areas: language, constructions, memory, calculations, and reasoning. 7 The examination separately assesses level of consciousness, orientation, and attention. While the NCSE quickly identifies intact areas of functioning, it also provides more detailed assessment in areas of dysfunction. The value of assessing cognitive function in nursing cannot be overstressed, as these symptoms profoundly affect community functioning and the ability of patients to lead lives they feel are of value (Figure 2). Patients want to return to work and have a sense of purpose, but neurocognitive symptoms prevent patients from realizing these fundamental needs and are significant in terms of long-term functioning. 10 Some research indicates that the newer antipsychotic agents have somewhat beneficial cognitive effects as compared with standard (US) doses of conventional agents; other research contradicts these findings, reporting mixed results regarding the cognitive effects of the newer antipsychotic agents. 11 Why is the research not more definitive? Part of the problem is the lack of a uniform standard for measuring outcomes for cognitive improvement the same problem that once confounded researchers studying Alzheimer s disease. Other factors that cloud research findings include variations in concomitant medications, side effects, and dosing, making it difficult to compare patients across all these spectrums. Finally, inaccurate diagnosis is a persistant problem, as many 148 Vol. 2, No. 4 October 2004
4 XASIN_2_4_p146_150 10/25/04 4:11 PM Page 149 of the negative symptoms of schizophrenia also appear in bipolar disorder and other forms of mania; psychosis, one of the major symptoms of schizophrenia, affects up to 80% of manic patients. 12 Nurses who work with veterans of war are especially aware that many patients in this population who suffered from hallucinations and other symptoms of posttraumatic stress syndrome may have received an inaccurate diagnosis of schizophrenia. Recent studies have attempted to modify study design to overcome issues that have skewed reporting in previous clinical trials. Cornblatt and colleagues compared aripiprazole 30 mg daily with olanzapine 10 mg and 15 mg daily in a 26-week open-label study of patients with schizophrenia or schizoaffective disorder (n = 255). 13 Patients were taking a stable dose of either risperidone or quetiapine for at least 1 month prior to enrollment and had not been hospitalized for at least 2 months. Although there was no statistical difference between the aripiprazole and olanzapine groups in symptoms, as evidenced by PANSS scores, there were observed differences in cognition. Over 8 weeks, the best improvement and most significant results were found in patients general overall cognitive function, with little difference between the antipsychotic agents. Verbal learning assessment both within clinical practice and clinical trial analyses is very important. Verbal learning involves the ability to acquire, store, and retrieve verbal information for more than a few minutes. Naturally, this ability affects many areas, such as the information nurses give patients regarding medications and the likelihood of patients following those instructions. Verbal learning affects important activities required in daily living as well as the success of treatment plans. Remembering information from a rehabilitation program, class, vocational setting, and clinic visit are all essential to patient outcome. Thus, patients verbal learning abilities profoundly affect the clinician s ability to care for them, making assessment of neurocognition and subcomponents of cognition essential to clinical practice. Clinicians now have access to potent new therapies, and continuing research into the possibilities of new antipsychotic agents targeting glutamate receptors will likely yield additional therapeutic gains. Only if these functions are adequately assessed, however, can the clinician identify the gains and the lapses patients are experiencing in their everyday lives. Figure 2. Cognition and Functional Outcome Problem Strategies for Dealing with Cognition Problems Difficulty with problem solving Difficulty processing information, following instructions Difficulty with verbal communication Difficulty expressing problems Nursing Intervention Realize that the patient sees every problem as having one solution. Teach patient to look at other possible solutions to problems. Realize that the patient often thinks there is only one way to do a task. Create alternative ways to approach situations. Give patients time to process and respond to information. Demonstrate genuine interest in trying to understand what the patient is saying. Be clear and simple when communicating with patient. Help patient break tasks into small sequential steps. Help patient to keep focused on a single task, one step at a time. Give directions to patient one step at a time in the order they are to be performed. Use active listening to understand the patient. Clarify what the patient is trying to tell you. Help patient with vocabulary as needed. Use the literal meaning of words. Have patient repeat back what was heard. Help patient understand the words and phrases used. Help patient to identify and prioritize needs and to express them in ways others will understand. Role play conversations. Source: Moller MD, Murphy MF. Neurobiological responses and schizophrenia and psychotic disorders. In: Stuart GW, Laraia MT, eds. Principles and Practice of Psychiatric Nursing. 7th ed. St. Louis: Mosby; 2001: Advanced Studies in Nursing 149
5 XASIN_2_4_p146_150 10/25/04 4:11 PM Page 150 Nursing Interventions to Prevent Relapse Identify symptoms that signal relapse Identify symptom triggers Select symptom management techniques Identify coping strategies for symptom triggers Identify support system for future relapse Document action plan in writing and file with key support people Facilitate integration into family and community Source: Moller MD, Murphy MF. Neurobiological responses and schizophrenia and psychotic disorders. In: Stuart GW, Laraia MT, eds. Principles and Practice of Psychiatric Nursing. 7th ed. St. Louis: Mosby; 2001: CLINICAL IMPLICATIONS Problems with cognition and verbal expression profoundly affect the nursing treatment plan and must be addressed in order to enhance recovery and to prevent relapse. Recommendations for assessing cognitive function and nursing interventions to help patients overcome such limitations can be found in the Sidebars. REFERENCES 1. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172: Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA- 79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1): Erratum in: N Engl J Med. 2002;346(18): Arato M, O'Connor R, Meltzer HY; ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5): Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64(9): Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4): Moller MD, Murphy MF. Nuerobiological responses and schizophrenia and psychotic disorders. In: Stuart GW, Laraia MT, eds. Principles and Practice of Psychiatric Nursing. 7th ed. St. Louis, Mo: Mosby; 2001: Kiernan RJ, Mueller J, Langston JW, Van Dyke C. The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med. 1987;107(4): Lamarre CJ, Patten SB. A clinical evaluation of the Neurobehavioral Cognitive Status Examination in a general psychiatric inpatient population. J Psychiatry Neurosci. 1994;19(2): Roper BL, Bieliauskas LA, Peterson MR. Validity of the MMSE and the NCSE in cognitive screening. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9: Green MF, Kern RS, Braff DC, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull. 2000;26(1): Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2): Goodwin F, KR. KJ. Manic-Depressive Illness. London, England: Oxford University Press; Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole vs olanzapine in stable psychosis. Int J Neuropsychopharmacol. 2002;5(5):S185-S Vol. 2, No. 4 October 2004
Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.
Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.
More informationPsychotic disorders are complex neurobiologic
XASIN_2_4_p135_145 10/25/04 3:40 PM Page 135 IMPROVING OUTCOMES FOR PATIENTS WITH PSYCHOTIC DISORDERS * Geoffry W. McEnany, RN, PhD, CS ABSTRACT In psychosis, appropriate prescribing and administration
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psychosis and schizophrenia in children and young people: recognition and management 1.1 Short title Psychosis and schizophrenia
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSchizophrenia and Other Psychotic Disorders
Schizophrenia and Other Psychotic Disorders Chapter 14 This multimedia product and its contents are protected under copyright law. The following are prohibited by law: any public performance or display,
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationSchizophrenia and Related Psychotic Disorders
and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder
More informationThe Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia
The Efficacy and Safety of Lower Doses of for the Treatment of Patients with Acute Exacerbation of Schizophrenia By Andrew J. Cutler, MD, Ronald N. Marcus, MD, Sterling A. Hardy, MS, Amy O Donnell, MD,
More information8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis
8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis Ruby S. Grewal, MD and Tony P. George, MD, FRCPC As cannabis consumption rises, there has been significant emerging evidence
More informationSchizophrenia. Introduction. Overview and Facts
Introduction is a chronic, severe and disabling brain disease that typically shows its first clear symptoms in late adolescence or early adulthood. It is one of several types of Psychotic Disorders. It
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationSchizophrenia and bipolar disorders are lifelong
THE STANDARD OF CARE IN TREATING PSYCHIATRIC DISORDERS Peter J. Weiden, MD,* and David G. Daniel, MD ABSTRACT In recent years, several guidelines and algorithms have appeared to help clinicians address
More informationPsychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com
Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More information8/22/2016. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd)
Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 16 Schizophrenia Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties, but can be as
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prescribing Pattern of Antipsychotics In A Tertiary Care Hospital, Salem: A Retrospective Study. B Arul 1 *, E Manivannan 2, R Kothai
More informationIs Asenapine More Effective than Other Interventions in the Treatment of Adult Patients with Bipolar I Disorder?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Asenapine More Effective than Other
More informationContemporary Psychiatric-Mental Health Nursing. Features of Schizophrenia. Features of Schizophrenia - continued
Contemporary Psychiatric-Mental Health Nursing Chapter 16 Schizophrenia and Other Psychotic Disorders Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties,
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationChapter 12. Schizophrenia and Other Psychotic Disorders. PSY 440: Abnormal Psychology. Rick Grieve Western Kentucky University
Chapter 12 Schizophrenia and Other Psychotic Disorders PSY 440: Abnormal Psychology Rick Grieve Western Kentucky University psychotic disorders disorders so severe that the person has essentially lost
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationNational Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS
National Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS Key Points for RWE in Randomized Clinical Trials What is the
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abuse substance. See Substance abuse Acquired disorders presenting as psychosis in children and young adults, 581 608. See also specific
More informationMental Health Nursing: Organic Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Organic Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Cognition Mental process characterized by knowing, thinking, learning, and judging Cognitive disorders include delirium
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationSchizophrenia: New Concepts for Therapeutic Discovery
Schizophrenia: New Concepts for Therapeutic Discovery William T. Carpenter, M.D. Professor of Psychiatry and Pharmacology University of Maryland School of Medicine Department of Psychiatry Maryland Psychiatric
More informationECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004 B
European Neuropsychopharmacology (2007) 17, 70 77 www.elsevier.com/locate/euroneuro ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004 B S.A. Montgomery
More informationPOT WEED CHRONIC GREEN KUSH BUD HERB
POT WEED CHRONIC GREEN KUSH BUD HERB WHAT MOTIVATES YOU TO USE POT?* AVOID USING CANNABIS RELAXES ME HELPS ME FIT IN HELPS ME FORGET MAKES ME FEEL HAPPY HELPS ME SLEEP CHANGES MY REALITY *Though there
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationUniversity of Groningen
University of Groningen A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole Schorr, S. G.; Slooff, C. J.; Postema, R.; Van Oven, W.; Schilthuis, M.; Bruggeman, Richard;
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationDepartment of Neuropsychiatry and Behavioral Sciences
Department of Neuropsychiatry and Behavioral Sciences The following pages contain a study guide to learning to conduct a mental status examination. Although this element of the physical exam is one of
More informationSCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS
1 SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS OBJECTIVES 2 Know and understand: How to evaluate a person with psychotic symptoms The epidemiology and clinical characteristics of lateonset schizophrenia
More informationSchizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13
Schizophrenia Chapter 13 Psychotic Disorders Symptoms Alternations in perceptions, thoughts, or consciousness (delusions and hallucination) DSM-IV categories Schizophrenia Schizophreniform disorder Schizoaffective
More informationAbstract: "Evidence-Based Psychotherapy for Schizophrenia: Past, Present, and Future (Intermediate)
Shaun M. Eack, PhD David E. Epperson Professor of Social Work and Professor of Psychiatry School of Social Work and Department of Psychiatry University of Pittsburgh Pittsburgh, PA Abstract: "Evidence-Based
More informationReview: Psychosocial assessment and theories of development from N141 and Psych 101
Unit III Theory and Practice of Psychiatric Nursing REQUIRED READINGS AND ACTIVITIES Related Activities Assignments Review: Psychosocial assessment and theories of development from N141 and Psych 101 Anxiety,
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationWeek #1 Classification & Diagnosis
Week #1 Classification & Diagnosis 3 Categories in the Conceptualisation of Abnormality Psychological Dysfunction: Refers to a breakdown in cognitive, emotional or behavioural functioning. Knowing where
More informationSwitching Patients with Chronic Schizophrenia to Aripiprazole: the Improvement in Cognitive Function
KISEP Original Article Clinical Psychopharmacology and Neuroscience 2006; 4: 32-39 Switching Patients with Chronic Schizophrenia to Aripiprazole: the Improvement in Cognitive Function Jung Goo Lee 1, Ji
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Schizophrenia and Cognition Jeffrey A. Lieberman, MD Columbia University College of Physicians and Surgeons New York State Psychiatric
More informationWest Midlands DEC Reports
30 March 1998 West Midlands DEC Reports 15 Appendices Appendix 1...32 Appendix 2...37 Appendix 3...39 Appendix 4...45 Appendix 5...52 March 1998 West Midlands DEC reports 31 Appendix 1 Evidence on efficacy
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationCLINICAL EFFECTIVENESS
CLINICAL EFFECTIVENESS Faculty Dr Ashok Malla Dr Rahul Manchanda Dr Toba Oluboka Dr Thomas Raedler Dr Marc-André Roy Dr Phil Tibbo Dr Richard Williams Audience Question What do you think Clinical Effectiveness
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2
Psychiatrická klinika LFUK a UNB, Bratislava SCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2 Author: MUDr. Ľubomíra Izáková, PhD. Supervisor: doc. MUDr. Ján Pečeňák, CSc. Podporené grantom
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPsychosis, Delirium, Dementia
Psychosis, Delirium, Dementia Melinda M. Spencer Smith, DNP, ACNS-BC, APRN Bertia A. Spencer Jennings, DNP, PPCNP, PMHS, BC Intentions and Limitations of Training Introduction Psychosis, Delirium, Dementia
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationOpen Translational Science in Schizophrenia. Harvard Catalyst Workshop March 24, 2015
Open Translational Science in Schizophrenia Harvard Catalyst Workshop March 24, 2015 1 Fostering Use of the Janssen Clinical Trial Data The goal of this project is to foster collaborations around Janssen
More informationMental Health Disorders Civil Commitment UNC School of Government
Mental Health Disorders 2017 Civil Commitment UNC School of Government Edward Poa, MD, FAPA Chief of Inpatient Services, The Menninger Clinic Associate Professor, Baylor College of Medicine NC statutes
More informationBipolar disorder, sometimes called manicdepressive
XXASIN_2_4_p151_157 10/25/04 3:45 PM Page 151 ROLE OF ANTIPSYCHOTIC MEDICATIONS IN TREATING BIPOLAR DISORDER * Mary Jane Strong, APRN, MS, CS ABSTRACT Although no cure exists for bipolar disorder, treatment
More informationEVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 7 (56) No. 1-2014 EVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationPsychological Disorders
Psychological Disorders Chapter 15 Class Objectives What are Mood Disorders? Depression, Mania and Bipolar What are Psychotic Disorders? Schizophrenia Moods THINK on your own What are some everyday moods
More informationMental Status Exam 101. A Concurrent Disorders Lunch & Learn
Mental Status Exam 101 A Concurrent Disorders Lunch & Learn 2 HELLO! Bradley Labuguen RN BScN MHM CPMHN(c) blabugue@stjosham.on.ca Nurse Educator St. Joseph s Healthcare Hamilton 3 Objectives Time: 50
More informationMethod. NeuRA Schizophrenia and bipolar disorder April 2016
Introduction Schizophrenia is characterised by positive, negative and disorganised symptoms. Positive symptoms refer to experiences additional to what would be considered normal experience, such as hallucinations
More informationDOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of schizophrenia family assessment and intervention treatment of schizophrenia
More informationEarly Stages of Psychosis. Learning Objectives
Early Stages of Psychosis Stephan Heckers, MD MSc Department of Psychiatry and Behavioral Sciences Vanderbilt University Learning Objectives Summarize the five domains of psychosis Describe how psychotic
More informationThe New England Journal of Medicine A COMPARISON OF RISPERIDONE AND HALOPERIDOL FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
A COMPARISON OF RISPERIDONE AND HALOPERIDOL FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA JOHN G. CSERNANSKY, M.D., RAMY MAHMOUD, M.D., M.P.H., AND RONALD BRENNER, M.D., FOR THE RISPERIDONE-USA-79
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationLurasidone for the treatment of schizophrenia. Lead author: Gavin Mankin Regional Drug & Therapeutics Centre (Newcastle) February 2015
Lurasidone for the treatment of schizophrenia Lead author: Gavin Mankin Regional Drug & Therapeutics Centre (Newcastle) February 2015 2015 Summary Lurasidone is a second generation (atypical) antipsychotic
More informationNetwork Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications
Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications JOHN M. DAVIS, MD Professor of Psychiatry University of Illinois at Chicago Chicago, Illinois and STEFAN LEUCHT, MD Klinik
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationFirst Episode Schizophrenia
First Episode Schizophrenia Abigail Donovan, M.D. Assistant Professor of Psychiatry, Harvard Medical School Director, First Episode and Early Psychosis Program MGH Schizophrenia Program Massachusetts General
More information8/23/2016. Chapter 34. Care of the Patient with a Psychiatric Disorder. Care of the Patient with a Psychiatric Disorder
Chapter 34 Care of the Patient with a Psychiatric Disorder All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. Care of the Patient with a Psychiatric
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena Otsuka Pharmaceuticals Co. & Lundbeck Canada Inc.) Indication: Schizophrenia Recommendation: The Canadian Drug Expert Committee
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationChapter 12 1/29/2018. Schizophrenia and Schizophrenia Spectrum Disorders. Epidemiology. Comorbidity. Lifetime prevalence of schizophrenia is 1%
Chapter 12 Schizophrenia and Schizophrenia Spectrum Disorders Epidemiology Lifetime prevalence of schizophrenia is 1% No difference related to 2 Comorbidity Substance abuse disorders Anxiety, depression,
More informationSchizoaffective Disorder
Roseanna Parkhurst-Gatewood MSN FNP-BC, PMHNP-BC DSM-5 diagnostic criteria for schizoaffective disorder 3 A. An uninterrupted period of illness during which there is a major mood episode (major depressive
More informationClinician-reported Outcomes (ClinROs), Concepts and Development
Clinician-reported Outcomes (ClinROs), Concepts and Development William Lenderking, PhD, Senior Research Leader; Dennis Revicki, PhD, Senior Vice President, Outcomes Research In heathcare, there are many
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationBy Jason H. King DECONSTRUCTING THE DSM-5 ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS THE NEW LANDSCAPE
DECONSTRUCTING THE DSM-5 By Jason H. King ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS Happy New Year as you engage in your counseling, research, supervision or educational endeavors. I
More informationComparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics
Research Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Dante M Durand,1, Phillip Harvey 1,2, Ricardo Cáceda 3 ABSTRACT Introduction: Clozapine
More informationPsychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives
Psychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives TANG Tze-Chun Department of psychiatry KMUH Pharmacotherapy alone or combination with psychotherapy?
More information9/3/2014. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd)
Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 16 Schizophrenia Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties, but can be as
More informationHandout 2: Understanding Psychotic Illness
Handout 2: Understanding Psychotic Illness A Psychosis refers to a state where a person loses contact with reality. The word is derived from the Latin words "psyche" meaning mind and "osis" meaning illness.
More informationReviews and Overviews. Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Reviews and Overviews Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Christoph U. Correll, M.D. Stefan Leucht, M.D. John M. Kane,
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationRisks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationCAN I REALLY USE THERAPY FOR PATIENTS WITH PSYCHOSIS?: COGNITIVE BEHAVIORAL THERAPY FOR SCHIZOPHRENIA SPECTRUM DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences CAN I REALLY USE THERAPY FOR PATIENTS WITH PSYCHOSIS?: COGNITIVE BEHAVIORAL THERAPY FOR SCHIZOPHRENIA SPECTRUM DISORDERS
More informationBipolar disorder is a lifelong debilitating PROCEEDINGS EVOLVING ROLE OF ANTIPSYCHOTIC THERAPY IN THE MANAGEMENT OF BIPOLAR DISORDER *
EVOLVING ROLE OF ANTIPSYCHOTIC THERAPY IN THE MANAGEMENT OF BIPOLAR DISORDER * Karen C. Tugrul, RN, BSN ABSTRACT The lifetime prevalence of bipolar I disorder in the United States is reported to be between
More informationResults of a Survey of Expert Clinicians on Psychosis Symptoms in Deaf Individuals
Results of a Survey of Expert Clinicians on Psychosis Symptoms in Deaf Individuals Robert Pollard, Ph.D. Deaf Wellness Center URMC Department of Psychiatry Deaf Wellness Center Staff Bob Pollard Amanda
More informationTaking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS Psychosis is highly treatable, especially if caught early. The prognosis for recovery
More information